Table 2.
Characteristics of patients categorized by GPS
| GPS: 0 (n = 42) | GPS: 1–2 (n = 38) | p value | |
|---|---|---|---|
| Age in years, median (range) | 73 (45–83) | 70 (44–86) | 0.64 |
| Sex | |||
| Male/female | 26/16 | 30/8 | 0.10 |
| Performance status | |||
| 0–1/2–3 | 31/11 | 22/16 | 0.13 |
| Histology | |||
| Squamous/non-squamous | 9/33 | 10/28 | 0.44 |
| Clinical stage at diagnosis | |||
| III or IV/recurrence | 35/7 | 33/5 | 0.66 |
| Mutation (EGFR/ALK) | |||
| Wildtype or unknown/mutant | 27/15 | 31/7 | 0.084 |
| Body mass index (kg/m2), median (range) | 22.6 (16.5–32.2) | 20.8 (16.5–27.0) | 0.14 |
| High (≥20.4)/low (<20.4) | 30/12 | 21/17 | 0.015 |
| Regimen | |||
| Pembrolizumab/atezolizumab | 28/14 | 21/17 | 0.30 |
| Smoking status | |||
| Current or former smoker/never smoker | 32/10 | 30/8 | 0.77 |
| TPS | |||
| <50%/≥50% | 24/18 | 28/10 | 0.12 |
| Treatment line | |||
| Second/third or subsequent | 22/20 | 17/21 | 0.49 |
GPS, Glasgow prognostic score; TPS, tumor proportion score.